Impact of different adjuvants on immunogenicity of the HBV particle vaccine containing the S + PreS1 fusion antigen in Balb/C mice

Shengwu Gongcheng Xuebao/Chinese Journal of Biotechnology

Volumn 26, Issue 1, 2010, Pages 74-78

  Chen, Hong ^a   Deng, Yao ^a   Tan, Wenjie ^a   Wang, Wen ^a   Yin, Xiao ^a   Guan, Jie ^a   Wang, Wenling ^a   Ruan, Li ^a  

^a CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

Author keywords

CpG ODN; Hepatitis B virus (HBV); Vaccine; Viral particles

Indexed keywords

CPG OLIGONUCLEOTIDE; CPG-OLIGONUCLEOTIDE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HYBRID PROTEIN; IMMUNOLOGICAL ADJUVANT; OLIGODEOXYRIBONUCLEOTIDE; PRESURFACE PROTEIN 1, HEPATITIS B SURFACE ANTIGEN; PROTEIN PRECURSOR; RECOMBINANT VACCINE;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; BIOSYNTHESIS; CHO CELL; CRICETULUS; FEMALE; GENETICS; HAMSTER; IMMUNIZATION; IMMUNOLOGY; MOUSE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CHO CELLS; CRICETINAE; CRICETULUS; FEMALE; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; IMMUNIZATION; MICE; MICE, INBRED BALB C; OLIGODEOXYRIBONUCLEOTIDES; PROTEIN PRECURSORS; RECOMBINANT FUSION PROTEINS; VACCINES, SYNTHETIC;

CRICETULUS GRISEUS; HEPATITIS B VIRUS; MUS;

EID: 77954826894     PISSN: 10003061     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Lavanchy D. Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention. J Clin Virol, 2005, 34(S1): S1-3.
2. Tan WJ, Ruan L. Progress on combination strategies of therapeutic vaccine approaches for the treatment of chronic HBV infection. Chin J Virol, 2006, 22(5): 407-411.
3. Tian SF, Zong F, Chen H, et al. The physicochemical and biological properties of SS1 fusion antigen of HBsAg secreted by mammalian cells. Chin J Virol, 2002, 18(4): 312-316.
4. Wang SQ, Xu HL, Ruan L, et al. Effects of CpG on the immune response to recombinant hepatitis B virus vaccine. Chin J Virol, 2002, 18(2): 108-112.
5. Davis HL, Weeratna R, Waldschmidt TJ, et al. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J Immunol, 1998, 160(2): 870-876.
6. Xu HL, Wang SF, Guo F, et al. CpG-ODN is a potential candidate adjuvant for human vaccines. Chin J Med, 2002, 82(8): 553-556.
7. 2+S) protein particles (a third generation vaccine). Vaccine, 1991, 9(3): 163-169.
8. Dash S, Rao KV, Panda SK. Receptor for pre-S1 (21-47) component of hepatitis B virus on the liver cell: role in virus cell interaction. J Med Virol, 1992, 37(2): 116-121.
9. Halperin SA, Van Nest G, Smith B, et al. A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant. Vaccine, 2003, 21(19/20): 2461-2467.
10. Zhang W, Du X, Zhao G, et al. Levamisole is a potential facilitator for the activation of Th1 responses of the subunit HBV vaccination. Vaccine, 2009, 27(36): 4938-4946.